Cellebrite Di Ltd Stock Price, News & Analysis

Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, has announced it will release its fourth-quarter and fiscal year 2024 financial results before market open on Thursday, February 13, 2025.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the Q4 2024 results and provide outlook for 2025. Historical financial tables and supplemental data will be made available on the company's investor relations website.

Cellebrite (NASDAQ: CLBT), a global leader in digital investigative solutions, has announced its participation in the upcoming Needham & Company 27th Annual Growth Conference.

The event will take place on January 14, 2025, with Cellebrite's presentation scheduled for 8:45 a.m. ET. The presentation format will be a Fireside Chat and can be accessed via the event URL: https://investors.cellebrite.com/events/event-details/needham-co-27th-annual-growth-conference.

Key executives representing Cellebrite at the conference will be Dana Gerner, Chief Financial Officer, and Andrew Kramer, Vice President, Investor Relations.

Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, announced key updates to its Board of Directors to bolster the company's growth in 2025 and beyond. As of January 1, 2025, Thomas E. Hogan has been confirmed as interim CEO, while maintaining his role on the Board, with plans to revert to chairman once a new CEO is appointed. Adam H. Clammer, Managing Partner of True Wind Capital Management, has taken on the role of board chairman, adhering to best practices in board governance by separating the CEO and board chair duties.

Additionally, Michael D. Capellas, with extensive leadership experience across top technology companies, joins Cellebrite's Board as a Class II director and the new lead independent director, replacing Adam Clammer. Capellas's notable roles include CEO positions at VCE, First Data , MCI, Compaq Computer , and President at Hewlett-Packard.

Capellas expressed enthusiasm for joining Cellebrite, highlighting his commitment to justice, safety, and security, and his alignment with the company's mission to combat child exploitation and trafficking.

D-Fend Solutions has secured $31M in a new investment round led by Israel Growth Partners (IGP), with participation from Vertex Ventures and Vertex Growth. The company, specializing in RF cyber-based counter-drone technology, reported over 60% year-over-year revenue growth and expansion across nearly 30 countries, including Five Eyes alliance, G7, and NATO member states.

The funding will support technological advancement, market expansion, and addressing evolving drone threats. D-Fend's flagship product, EnforceAir, uses RF cyber-takeover techniques to neutralize rogue drones safely without operational disruption. The technology has been recognized by Booz Allen Hamilton and is deployed to protect military zones, airports, critical infrastructure, prisons, and public events.

Cellebrite (NASDAQ: CLBT), a global leader in Digital Investigative solutions, announced its participation in the upcoming UBS Global Technology and AI Conference. The company will participate in a fireside chat on December 3, 2024, at 4:55 p.m. ET. Key executives attending include Thomas Hogan (executive chairman), Dana Gerner (CFO), and Andrew Kramer (VP of investor relations).

Cellebrite (Nasdaq: CLBT) and Relativity announced the general availability of Cellebrite's mobile collection solutions integration into RelativityOne platform. The integration enables faster and more efficient mobile data management in legal processes. Following a successful Advanced Access program in July 2024, users reported significant efficiency gains, reducing mobile device data collection time to just over an hour compared to previous days or weeks. The integration allows remote mobile device collections to be fully orchestrated within RelativityOne, including custodian notification and automatic data transfer. According to Cellebrite's 2024 Industry Trends survey, 97% of eDiscovery cases now involve at least one mobile device.

Cellebrite reported strong Q3 2024 financial results, achieving a significant milestone with quarterly revenue exceeding $100 million for the first time. Revenue reached $106.9 million, up 27% year-over-year, driven by 27% growth in subscription revenue to $93.4 million. The company's Annual Recurring Revenue (ARR) grew 26% to $370.8 million, with a net retention rate of 124%.

Key highlights include adjusted EBITDA of $31.3 million with a 29.3% margin. The company announced Pathfinder in the Cloud with AWS and received a patent for Remote Mobile Collection. Based on strong performance, Cellebrite increased its 2024 outlook for revenue to $397-401 million and adjusted EBITDA to $94-100 million, while raising the low end of its ARR target range to $390-400 million.

Cellebrite (NASDAQ: CLBT) announced that CEO Yossi Carmil will step down from his position and Board of Directors by December 31, 2024. Executive Chairman Thomas E. Hogan will serve as interim CEO while the company conducts a formal search for a new chief executive. Under Carmil's 19-year leadership, Cellebrite grew from 18 to over 1,100 employees, expanded to dozen offices worldwide, and serves approximately 7,000 customers in more than 100 countries. Notable achievements include taking the company public in 2021, transitioning to a subscription business model, and launching the AI-driven Case-to-Closure platform. The company's market valuation has doubled to approximately $4 billion since going public.

Cellebrite (NASDAQ: CLBT) reported strong Q3 2024 results, achieving a milestone of $106.9 million in quarterly revenue, up 27% year-over-year. Subscription revenue grew 27% to $93.4 million, while Annual Recurring Revenue (ARR) reached $370.8 million, up 26% year-over-year. The company reported an Adjusted EBITDA of $31.3 million with a 29.3% margin. Despite posting a GAAP net loss of $207.1 million, non-GAAP net income was $31.8 million. Based on strong performance, Cellebrite increased its 2024 outlook for revenue and adjusted EBITDA, raising the low end of the ARR target range to $390-400 million.